Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CLK1 | P49759 | 9/20 | 0.63 |
| ▸ | DYRK1A | Q13627 | 4/20 | 0.63 |
| ▸ | DYRK1B | Q9Y463 | 2/20 | 0.63 |
| ▸ | ICAM1 | P05362 | 1/20 | 0.49 |
| ▸ | SELE | P16581 | 1/20 | 0.49 |
| ▸ | CYP2A6 | P11509 | 4/20 | 0.47 |
| ▸ | CLK2 | P49760 | 3/20 | 0.44 |
| ▸ | CHEK1 | O14757 | 1/20 | 0.44 |
| ▸ | AURKA | O14965 | 1/20 | 0.44 |
| ▸ | DAPK3 | O43293 | 1/20 | 0.44 |
| ▸ | PRKD3 | O94806 | 1/20 | 0.44 |
| ▸ | MAP4K4 | O95819 | 1/20 | 0.44 |
| ▸ | PAK4 | O96013 | 1/20 | 0.44 |
| ▸ | ABL1 | P00519 | 1/20 | 0.44 |
| ▸ | RET | P07949 | 1/20 | 0.44 |
| ▸ | PIM1 | P11309 | 1/20 | 0.44 |
| ▸ | FGFR1 | P11362 | 1/20 | 0.44 |
| ▸ | PRKACA | P17612 | 1/20 | 0.44 |
| ▸ | FLT1 | P17948 | 1/20 | 0.44 |
| ▸ | LTK | P29376 | 1/20 | 0.44 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL13977426 | 0.89 | CLK1 (0.59) | CLK1DYRK1ADYRK1BICAM1SELE | |
| SCHEMBL160500 | 0.80 | CDK8 (0.49) | DYRK1ADYRK1BICAM1SELECYP2A6 | |
| SCHEMBL11888470 | 0.80 | CLK1 (0.69) | CLK1DYRK1ADYRK1BCLK2LMNA | |
| SCHEMBL20955548 | 0.78 | CYP2A6 (0.58) | CLK1DYRK1ADYRK1BCYP2A6CLK2 | |
| SCHEMBL2009820 | 0.77 | DYRK1A (0.56) | CLK1DYRK1ADYRK1BICAM1SELE | |
| SCHEMBL10239002 | 0.77 | CLK1 (0.74) | CLK1DYRK1ADYRK1BICAM1SELE | |
| SCHEMBL10238993 | 0.77 | CLK1 (1.00) | CLK1DYRK1ADYRK1BCLK2CLK4 | |
| SCHEMBL7928289 | 0.77 | CLK1 (0.74) | CLK1DYRK1ADYRK1BCLK2CLK4 | |
| SCHEMBL10855370 | 0.76 | HDAC1 (0.49) | DYRK1ADYRK1BICAM1SELECYP2A6 | |
| SCHEMBL844056 | 0.76 | BCL2L1 (0.58) | DYRK1ADYRK1BCYP2A6CLK2CHEK1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 57 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20260062443-A1 | PHARMACEUTICAL COMPOUNDS FOR THE TREATMENT OF COMPLEMENT MEDIATED DISORDERS | ALEXION PHARMA INC (US) | 2026-03-05 | — | — | US | disclosed |
| US-20250099462-A1 | Certain Triazolopyridines and Triazolopyrazines, Compositions Thereof and Methods of Use Therefor | HUTCHISON MEDIPHARMA LTD (CN) | 2025-03-27 | — | — | US | disclosed |
| US-20240139182-A1 | Certain Triazolopyridines and Triazolopyrazines, Compositions Thereof and Methods of Use Therefor | HUTCHISON MEDIPHARMA LTD (CN) | 2024-05-02 | — | — | US | disclosed |
| WO-2024044098-A2 | PHARMACEUTICAL COMPOUNDS FOR THE TREATMENT OF COMPLEMENT MEDIATED DISORDERS | ALEXION PHARMACEUTICALS, INC. (US) | 2024-02-29 | — | — | WO | disclosed |
| US-11896592-B2 | Certain triazolopyridines and triazolopyrazines, compositions thereof and methods of use therefor | HUTCHISON MEDIPHARMA LIMITED (CN) | 2024-02-13 | — | — | US | disclosed |
| EP-3795573-B1 | CERTAIN TRIAZOLOPYRAZINES, COMPOSITIONS THEREOF AND METHODS OF USE THEREFOR | HUTCHISON MEDIPHARMA LTD (CN) | 2022-07-06 | — | — | EP | disclosed |
| US-20210154192-A1 | CERTAIN TRIAZOLOPYRIDINES AND TRIAZOLOPYRAZINES, COMPOSITIONS THEREOF AND METHODS OF USE THEREFOR | HUTCHISON MEDIPHARMA LIMITED (CN) | 2021-05-27 | — | — | US | disclosed |
| US-20210154192-A1 | CERTAIN TRIAZOLOPYRIDINES AND TRIAZOLOPYRAZINES, COMPOSITIONS THEREOF AND METHODS OF USE THEREFOR | HUTCHISON MEDIPHARMA LIMITED (CN) | 2021-05-27 | — | — | US | disclosed |
| EP-3795573-A1 | CERTAIN TRIAZOLOPYRIDINES AND TRIAZOLOPYRIDINES, COMPOSITIONS THEREOF AND METHODS OF USE THEREFOR | Hutchison Medipharma Limited (CN) | 2021-03-24 | — | — | EP | disclosed |
| US-10954232-B2 | Pyrazole derivative as ALK5 inhibitor and uses thereof | HANMI PHARMACEUTICAL CO., LTD. (KR) | 2021-03-23 | — | — | US | disclosed |
| US-20120264739-A1 | CERTAIN TRIAZOLOPYRIDINES AND TRIAZOLOPYRAZINES, COMPOSITIONS THEREOF AND METHODS OF USE THEREFOR | HUTCHISON MEDIPHARMA LIMITED (CN) | 2012-10-18 | — | — | US | disclosed |
| US-20120245178-A1 | CERTAIN TRIAZOLOPYRIDINES AND TRIAZOLOPYRAZINES, COMPOSITIONS THEREOF AND METHODS OF USE THEREFOR | HUTCHISON MEDIPHARMA LIMITED (CN) | 2012-09-27 | — | — | US | disclosed |
| US-20120245178-A1 | CERTAIN TRIAZOLOPYRIDINES AND TRIAZOLOPYRAZINES, COMPOSITIONS THEREOF AND METHODS OF USE THEREFOR | HUTCHISON MEDIPHARMA LIMITED (CN) | 2012-09-27 | — | — | US | disclosed |
| US-20120245178-A1 | CERTAIN TRIAZOLOPYRIDINES AND TRIAZOLOPYRAZINES, COMPOSITIONS THEREOF AND METHODS OF USE THEREFOR | HUTCHISON MEDIPHARMA LIMITED (CN) | 2012-09-27 | — | — | US | disclosed |
| US-20110224251-A1 | Therapeutic Pyrazolyl Thienopyridines | GRACEWAY PHARMACEUTICALS, LLC (US) | 2011-09-15 | — | — | US | disclosed |
| WO-2011079804-A1 | CERTAIN TRIAZOLOPYRIDINES AND TRIAZOLOPYRAZINES, COMPOSITIONS THEREOF AND METHODS OF USE THEREFOR | HUTCHISON MEDIPHARMA LIMITED (CN) | 2011-07-07 | — | — | WO | disclosed |
| US-7964612-B2 | Therapeutic pyrazolyl thienopyridines | GRACEWAY PHARMACEUTICALS, LLC (US) | 2011-06-21 | — | — | US | disclosed |
| EP-2074128-A1 | THERAPEUTIC PYRAZOLYL THIENOPYRIDINES | Pfizer Products Incorporated (US) | 2009-07-01 | — | — | EP | disclosed |
| WO-2008047198-A1 | THERAPEUTIC PYRAZOLYL THIENOPYRIDINES | PFIZER PRODUCTS INC. (US) | 2008-04-24 | — | — | WO | disclosed |
| US-20080090861-A1 | Cancer and fibrotic disorders such as scarring prevention; 2-(4-methyl-1-(6-methylpyridin-2-yl)-1H-pyrazol-5-yl)thieno[2,3-c]pyridine for example; activin receptor-like kinase-5 (ALK-5) inhibitors | PFIZER INC. | 2008-04-17 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (10 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20120245178-A1 | CERTAIN TRIAZOLOPYRIDINES AND TRIAZOLOPYRAZINES, COMPOSITIONS THEREOF AND METHODS OF USE THEREFOR | KCNJ11, NISCH, CYP4Z1 | CLK1 2923/4885DYRK1A 3409/4885DYRK1B 3442/4885 |
| US-20260062443-A1 | PHARMACEUTICAL COMPOUNDS FOR THE TREATMENT OF COMPLEMENT MEDIATED DISORDERS | C9, SSB, C1S | CLK1 4130/4885DYRK1A 4308/4885DYRK1B 3933/4885 |
| US-20120264739-A1 | CERTAIN TRIAZOLOPYRIDINES AND TRIAZOLOPYRAZINES, COMPOSITIONS THEREOF AND METHODS OF USE THEREFOR | KCNJ11, NISCH, CYP4Z1 | CLK1 2923/4885DYRK1A 3409/4885DYRK1B 3442/4885 |
| US-20210154192-A1 | CERTAIN TRIAZOLOPYRIDINES AND TRIAZOLOPYRAZINES, COMPOSITIONS THEREOF AND METHODS OF USE THEREFOR | KCNJ11, NISCH, CYP4Z1 | CLK1 2923/4885DYRK1A 3409/4885DYRK1B 3442/4885 |
| US-20110224251-A1 | Therapeutic Pyrazolyl Thienopyridines | TGFBR1, SMAD3, TGFBR2 | CLK1 4463/4885DYRK1A 3025/4885DYRK1B 3007/4885 |
| US-11896592-B2 | Certain triazolopyridines and triazolopyrazines, compositions thereof and methods of use therefor | TK2, TYMP, DPYD | CLK1 2756/4885DYRK1A 1786/4885DYRK1B 1967/4885 |
| US-20250099462-A1 | Certain Triazolopyridines and Triazolopyrazines, Compositions Thereof and Methods of Use Therefor | KCNJ11, NISCH, CYP4Z1 | CLK1 2923/4885DYRK1A 3409/4885DYRK1B 3442/4885 |
| US-20080090861-A1 | Cancer and fibrotic disorders such as scarring prevention; 2-(4-methyl-1-(6-methylpyridin-2-yl)-1H-pyrazol-5-yl)thieno[2,3-c]pyridine for example; activin receptor-like kinase-5 (ALK-5) inhibitors | ACVR1, TGFBR1, ACVRL1 | CLK1 3461/4885DYRK1A 1811/4885DYRK1B 1795/4885 |
| US-10954232-B2 | Pyrazole derivative as ALK5 inhibitor and uses thereof | ALK, SMAD3, TGFBR1 | CLK1 2710/4885DYRK1A 1319/4885DYRK1B 1196/4885 |
| US-20240139182-A1 | Certain Triazolopyridines and Triazolopyrazines, Compositions Thereof and Methods of Use Therefor | KCNJ11, NISCH, CYP4Z1 | CLK1 2923/4885DYRK1A 3409/4885DYRK1B 3442/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.